The pharmaceutical forum of the 23rd China Intellectual Property & Innovation Summit (CIPIS), organized by Conways, was held in Suzhou on July 2–3, 2026. Focusing on key intellectual property challenges facing the biopharmaceutical industry, the forum brought together industry professionals to exchange insights on global patent strategies, risks associated with cross-border transactions, IP dispute resolution, and other critical issues shaping innovation and growth in the sector.

Dr. LIU Guojun, Dr. CAO Lili, and Dr. MOU Ke, Partners at Liu Shen, together with JIANG Lan, JIA Lichen, GUO Yawen, and XIANG Nan, attended the summit on behalf of the firm. The team engaged in in-depth discussions with fellow IP professionals from various sectors, highlighting Liu Shen's extensive experience and expertise in pharmaceutical intellectual property matters.                                              

On the morning of July 2, Dr. MOU Ke delivered a keynote presentation entitled "Global IP Strategies and Risk Management for Biopharmaceutical Companies". His presentation provided a comprehensive analysis of the strategic value, practical approaches, and key risk considerations involved in the global expansion of biopharmaceutical businesses. Drawing on case studies involving prominent pharmaceutical products and development programs, including zanubrutinib, Roche's GLP-1 receptor agonist program, Moderna's COVID-19 vaccine, and Daiichi Sankyo's Enhertu, Dr. MOU explored the complexities of international IP strategies and associated risks. His analysis offered valuable insights for biopharmaceutical companies seeking to strengthen their global IP positions, manage legal and commercial risks, and pursue sustainable international growth.

Through a structured analytical framework and detailed case studies, Dr. MOU provided practical guidance on developing effective global IP strategies and implementing risk management measures. His presentation also demonstrated Liu Shen's capabilities in addressing complex intellectual property issues in the biopharmaceutical sector.

Throughout the summit, the Liu Shen team engaged in productive discussions with representatives from multinational pharmaceutical companies, innovative biotechnology firms, and investment institutions. The exchanges covered a range of practical topics, including patent portfolio development, freedom-to-operate (FTO) analysis, and licensing negotiation strategies, providing valuable opportunities to strengthen industry connections and facilitate professional knowledge sharing.